GGrantIndex
← Search

Molecular Oncology Program

$11,775P30FY2018CANIH

University Of California At Davis, Davis CA

Investigators

Linked publications, trials & patents

Paper 39725713Paper 39620216Paper 39616300Paper 39488208Paper 39453739Paper 39440945Paper 39384967Paper 39383000Paper 39350111Paper 39345479Paper 39345391Paper 39257973Paper 39252929Paper 39217266Paper 39177582Paper 39168154Paper 39108503Paper 39103353Paper 39056190Paper 39046599Paper 39012466Paper 38990223Paper 38979288Paper 38969563Paper 38947002Paper 38885336Paper 38877132Paper 38865710Paper 38843382Paper 38826195Paper 38803393Paper 38798575Paper 38780011Trial NCT07304011Trial NCT07258446Trial NCT07209215Trial NCT07189195Trial NCT07145112Trial NCT06905509Trial NCT06854159Trial NCT06211335Trial NCT06178354Trial NCT06173362Trial NCT06173349Trial NCT06103682Trial NCT06103669Trial NCT06067776Trial NCT05967533Trial NCT05843448Trial NCT05600686Trial NCT05479578Trial NCT05110781Trial NCT05101356Trial NCT05052528Trial NCT04964505Trial NCT04905810Trial NCT04856189Trial NCT04716699Trial NCT04587687Trial NCT04578600Trial NCT04552704Trial NCT04450173Trial NCT04410302Trial NCT04186988Trial NCT04050085Trial NCT04030559Trial NCT03695250Trial NCT03359460Trial NCT03299088Trial NCT03164486Trial NCT03123978Trial NCT02997761Trial NCT02935205Trial NCT02823990Trial NCT02807805Trial NCT02569723Trial NCT02400814Trial NCT02364609Trial NCT02348255Trial NCT02339168Trial NCT02178241Trial NCT02077998Trial NCT01924260Trial NCT01923337Trial NCT01911507Trial NCT01008566Trial NCT00918645Trial NCT00810719Trial NCT00804310Trial NCT00795665Trial NCT00628654Trial NCT00467077Trial NCT00408499Trial NCT00390429Trial NCT00389922Trial NCT00388115Trial NCT00388089Trial NCT00387660Trial NCT00387322Trial NCT00376727

Abstract

PROJECT SUMMARY/ABSTRACT The Molecular Oncology Program represents one of the two basic science fundaments to the University of California, Davis Comprehensive Cancer Center. The novel discoveries emanating from the program form the scientific underpinning of the translational and clinical cancer research to develop innovative modalities in the diagnosis and treatment of cancer. The two overarching topics of 1) Oncogenic Signaling and 2) Mechanisms of Genome Stability continue serving well to coalesce an eminent group of investigators into a cohesive program that through collaborations with one another and with numerous investigators in the other Cancer Center programs ensures that their discoveries are translated from the bench to the bedside. The Molecular Oncology Program strategically focuses on in vitro model systems leveraging the strength in biological research at UC Davis. This approach is complemented by associated in vivo studies using animal models conducted by the members in the Comparative Oncology Program. A significant pipeline of lead studies has been brought to clinical trials in cooperation with the Cancer Therapeutics and the Prostate Urothelial Cancer Program. Extending our strength in DNA repair to the analysis of cancer risk in human populations is the subject of collaborations with the Population Sciences & Health Disparities Program. A long- standing collaboration connects the studies in hormone receptor biology with translational and clinical studies in the Prostate Urothelial Cancer Program. The high-end technology and analysis tools developed and utilized by members in the Biomedical Technology Program enabled program members to better analyze molecular and cellular processes. SCIENTIFIC THEMES 1.Cytoplasmic Signaling and Chromosome Dynamics 2. Nuclear Signaling and Genome Stability ? Nuclear receptors and chromatin remodeling ? DNA repair and chromosome segregation ? Oncogenic signals transmitted to the nucleus ? Oncogenic signals emanating from the nucleus PROGRAM ASPECTS Co-leaders: Kermit Carraway, PhD, Wolf-Dietrich Heyer, PhD Members: 36 Total Grant Funding (ADC): $9.2 million Total Peer-Reviewed Funding (ADC): $8.7 million Total NCI funding (ADC): $2.7 million Total No. Publications: 464 Inter-programmatic publications: 102 (22%) Intra-programmatic publications: 47 (10%) Multi-institutional publications: 219 (47%) The membership of the Molecular Oncology Program remains at a dynamic steady state of 36 from 12 different department and 4 different schools at UC Davis, as well as LLNL. The total peer-reviewed, cancer-related funding (annual direct cost) has slightly declined to $9.2 million (from $10.8 million at the last competitive renewal) due to sequestration and the departure or retirement of several well-funded senior members. However, our NCI funding has even slightly increased (from $2.4 to $2.7 million) with 18 projects funded by NCI (17 at the last competitive renewal). The funding data exclude the HHMI funding of Dr. Hunter (~$1 million/yr direct cost) and VA funding to Dr. Chen ($191k/yr direct cost), effectively raising our total funding to $10.4 million, almost en par with our previous funding level. Typical for a basic science program, 20 of 36 members are located in basic sciences departments of the University of California, Davis, and their research in basic cancer biology is traditionally funded by NIHGMS. Since the summary funding report was assembled, one application received a fundable score (5%, NIGMS application to Dr. Roth), and Dr. Diaz obtained funding by the Whitehall Foundation with $225k/yr direct cost.

View original record on NIH RePORTER →